Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,800 JPY | +1.20% | +0.61% | +43.05% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company appears to be poorly valued given its net asset value.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+43.05% | 1.82B | B- | ||
+35.37% | 664B | C+ | ||
+29.64% | 567B | B | ||
-7.18% | 354B | C+ | ||
+19.50% | 330B | B- | ||
+4.55% | 286B | C+ | ||
+13.49% | 234B | B+ | ||
+5.28% | 199B | B- | ||
-9.90% | 196B | A+ | ||
-4.77% | 148B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4540 Stock
- Ratings Tsumura & Co.